TL;DR
This study investigated preserved ratio impaired spirometry (PRISm) patients, a group at high risk for chronic obstructive pulmonary disease (COPD) exacerbations. They found that while inhalation therapy significantly reduces exacerbation risk, specific drug combinations didn't show differential benefits, suggesting simpler treatments like mono-LAMA might be sufficient.
What Problem Does This Paper Address?
Preserved ratio impaired spirometry (PRISm) is a common pulmonary dysfunction closely linked to COPD. While PRISm patients are known to be at increased risk for exacerbations, there's a lack of clarity on the specific risk factors and how different inhalation therapies impact their outcomes. This study aims to fill this gap by identifying key risk factors for future exacerbations in PRISm patients and evaluating the effectiveness of various inhalation therapy regimens. Understanding these factors is crucial for developing targeted interventions to prevent severe exacerbations and improve patient management.
Methods
This was a retrospective cohort study that registered patients from the "Real-world study on the status of diagnosis and treatment of COPD (RealDTC)" between January 2017 and August 2024. Patients were diagnosed with PRISm based on GOLD 2024 guidelines (FEV1/FVC ≥ 0.7 and FEV1%pred < 0.8 after bronchodilator). Data collected included demographics, pulmonary function, symptom scores, past exacerbations and hospitalizations, inhalation therapy regimens, and comorbidities. The primary outcomes measured were future exacerbations, frequent exacerbations, hospitalizations, and all-cause mortality over a one-year follow-up period. Statistical analysis involved t-tests, non-parametric tests, chi-squared tests, and multivariate logistic regression to identify risk factors. Propensity score matching (PSM) was used to compare patients with and without inhalation therapy.
Datasets
The study utilized data from the "Real-world study on the status of diagnosis and treatment of COPD (RealDTC)" cohort, collected between January 2017 and August 2024. This is a real-world dataset, not a newly introduced benchmark.
Key Insights and Ideas
- PRISm is a significant risk factor for exacerbations: The study confirms that patients with PRISm are indeed at a high risk of experiencing future exacerbations.
- Inhalation therapy is protective: Providing inhalation therapy to PRISm patients demonstrably reduces their risk of future exacerbations, frequent exacerbations, and hospitalizations.
- Simplicity might be key for therapy: While various inhalation therapy combinations (LAMA, LABA+LAMA, LABA+ICS, LABA+LAMA+ICS) were analyzed, no significant differences in outcomes were found between them. This suggests that simpler, potentially mono-LAMA therapy, might be sufficient for managing exacerbation risk in PRISm patients, avoiding potentially unnecessary complex treatments.
- Age and prior hospitalizations are key risk factors: Older age and a history of hospitalizations in the past year were identified as independent risk factors for future exacerbations in PRISm patients.
Key Results
- Out of 648 initially included patients, 575 were analyzed after a one-year follow-up.
- 144 (25.0%) patients experienced exacerbations during the follow-up year.
- Independent risk factors for exacerbations included:
- Age (OR=1.026)
- Number of hospitalizations in the past year (OR=2.186)
- Lack of inhalation therapy (OR=8.382)
- After propensity score matching, patients without inhalation therapy had significantly higher rates of exacerbations, frequent exacerbations, and hospitalizations compared to those with inhalation therapy.
- No significant differences in future exacerbations, frequent exacerbations, hospitalizations, or all-cause mortality were observed among the different inhalation therapy groups (LAMA, LABA+LAMA, LABA+ICS, LABA+LAMA+ICS).
Limitations and Future Work
The authors acknowledge several limitations:
- Sample Size: While a multicenter study, the sample size is considered relatively small, suggesting a need for larger studies.
- Limited Data on Certain Therapies: The study had a small number of patients using mono-SABA, SAMA, or LABA, making it difficult to assess their efficacy compared to mono-LAMA.
- Short Follow-up Period: The one-year follow-up might be too short to fully capture long-term effects, especially regarding mortality.
- Real-World vs. RCT: The study is a real-world observation, and while PSM was used, confounding by indication may persist. The authors suggest that future confirmatory studies should adopt Randomized Controlled Trial (RCT) designs.
- Heterogeneity of PRISm: The diverse nature of PRISm might influence treatment responses.
- Unaccounted Factors: The influence of healthcare access, socioeconomic status, or prescribing patterns on pulmonary function trajectories and exacerbations remains unclear.
Future work should focus on larger, prospective RCTs to confirm these findings and explore the optimal treatment strategies for PRISm patients, potentially focusing on simpler, cost-effective therapies like mono-LAMA.
Summary updated